SEP 16, 2015 5:00 AM PDT

Synthetic Chemists to Aid the Community for Open Antimicrobial Drug Discovery

Speaker
  • Program Coordinator: Community for Open Antimicrobial Drug Discovery, University of Queensland
    Biography
      Dr. Mark Blaskovich is Program Coordinator: Hit Validation & Chemistry for the Community for Open Antimicrobial Drug Discovery, and a Senior Research Officer at the Institute for Molecular Bioscience at The University of Queensland. He has extensive medicinal chemistry expertise and over 15 years of industrial drug development experience, most recently as Chief Operating Officer at Mimetica (Australia), where he managed the drug discovery and development program for melanocortin-5 receptor antagonists leading to a compound currently in Phase II human trials for treatment of acne. In his previous role at CEPTYR (Seattle) he led a multidisciplinary team that developed a preclinical candidate for protein tyrosine phosphatase 1B, while at Molecumetics (Seattle) he headed a $2m/yr industrial collaboration on peptidomimetic compounds targeting proteases and GPCRs. Since starting at The University of Queensland, Mark has been working on developing new antibiotics to treat drug resistant pathogens. He has published over thirty articles, is an inventor on eight patent families with over 100 granted and pending applications, and is author of 'The Handbook on Syntheses of Amino Acids'.

    Abstract
    The antibiotic pipeline is broken, with a dearth of new antibiotics, a collapse in pharmaceutical company research1, and the exhaustion of chemical diversity contained in pharma libraries. "The low hanging fruit from the antibiotic tree has probably already been picked and new sources of compounds are needed."2 We believe that there is an untapped resource contained in the laboratories of synthetic organic chemists; synthetic compounds prepared for other projects that have never been tested for their antimicrobial potential. These compounds, which are sitting at the back of benches and freezers, may have been synthesised to validate new synthetic routes, develop new methodologies, or create unusual structures. A global screening initiative will uncover this significant and rich chemical diversity held outside of corporate screening collections by providing a low-barrier access to testing. Antibacterial drugs occupy a unique property space that is vastly different to drugs developed for other therapeutic areas, suggesting that commercially available chemical compounds lack the physicochemical properties ideal for activity against bacteria and therefore, a varied source of chemical diversity needs to be investigated. We have created a Wellcome Trust-supported not-for-profit Open-Access initiative, The Community for Open Antimicrobial Drug Discovery [CO-ADD], to provide unencumbered free antimicrobial screening for any interested researcher.3 CO-ADD builds upon a suite of established in vitro and in vivo assays, medicinal chemistry and core researcher expertise and aims to unearth fresh chemical diversity for the treatment of bacterial infection.

    Show Resources
    You May Also Like
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    JUN 09, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 09, 2020 10:00 AM PDT
    DATE: June 9, 2020 TIME: 10:00am PT, 1:00pm ET The presentation will first discuss sepsis as a disease and then explain the importance of performing diagnostic tests in the clinical labora...
    MAR 03, 2020 9:00 AM JST
    C.E. CREDITS
    MAR 03, 2020 9:00 AM JST
    DATE: March 3, 2020 TIME: 9:00am JST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid differentiation of HSPCs at the e...
    FEB 25, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 25, 2020 9:00 AM PST
    Learn about how to generate a small scale CAR-T workflow using ThermoFisher products See detailed characterization tools that can be utilized and applied in a CAR-T workflow...
    Loading Comments...
    Show Resources
    Attendees
    • See more